Login to Your Account



Hua's GKA passes POC; promise for growing diabetic space in China

By Shannon Ellis
Staff Writer

Tuesday, October 18, 2016

SHANGHAI – Hua Medicine Ltd. released the top-line results from the phase II trial of HMS5552, a fourth-generation GKA used as a single drug to treat type 2 diabetes patients in China.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription